The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. The test contains the respective primers and probes provided in the ready-made 384-test cassette. a SARS-CoV-2 rapid antibody test to help determine at the point of care whether a person has been exposed to the virus (CE Mark).

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

DECEMBER 31, 2020

Antibodies Respond Differently to Severe Versus Mild COVID-19. Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. People with severe COVID-19 have low proportions of antibodies that target the spike protein.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. Alexion ‘s franchise includes Soliris (eculizumab), a first-in-class anti-complement component 5 (C5) monoclonal antibody.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

AUGUST 10, 2022

Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Later, scientists took advantage of antibodies’ natural tendency to seek out specific antigens and created antibody therapies that guide T cells towards the cells they are supposed to destroy.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

JANUARY 14, 2021

False negative results can occur with any molecular test, particularly if a mutation occurs in the part of the virus’s genome assessed by that test. This variant contains the same N501Y mutation as B.1.1.7 However, it has a more concerning E484K mutation that may lower antibody recognition. In addition to B.1.1.7, 1.135 or 501.V2

Genetics 98

Genetics Genome Genomics Protein 98

The Pharma Data

MARCH 20, 2021

Cell culture for virus isolation also remains a useful method for growing and studying viruses in research settings especially in the characterization of novel pathogenic viruses like SARS-CoV-2 although this requires more advanced containment facilities such as biosafety level 3 (BSL-3). SARS-CoV-2 proteome. Protein extraction optimization.

Protein 52

Protein Antibody Development RNA 52

The Pharma Data

SEPTEMBER 16, 2020

Based on previous studies of other monoclonal antibodies, subcutaneous is generally a preferred route of administration by patients, physicians, healthcare providers and can be associated with hospital time- and cost-savings. Presentation #283MO (Oral), Friday, 18 September (On-demand). Lung cancer. Alecensa ® (alectinib). Real world data.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

MAY 7, 2021

The decision to start the rolling review is based on the interim analysis of efficacy and safety data from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial, which evaluated sotrovimab as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation.

Antibody 52

Antibody Trials Vaccination Vaccine 52

Drug Discovery World

MAY 11, 2023

In these cases, injection of the viral vector vaccines induced the production of antibodies recognising platelet factor 4 (PF4) found on patients’ platelets 1. These assays require large quantities of high-affinity anti-HCP antibodies and still fail to cover the complete HCP profile. These host cells alone contain over a thousand HCPs.

Production 52

Production Gene Protein Vaccination 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

SEPTEMBER 18, 2020

Having already acquired UK-based Cambridge Antibody Technology in 2006, AstraZeneca merged these two companies to create a dedicated global biologics organisation known as MedImmune. However many analysts felt the company had paid far too much for the US-based company, especially as it had few late-stage drugs with major commercial potential.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

Drug Discovery World

OCTOBER 12, 2022

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.

Protein 52

Protein Gene Therapy Antibody Production 52

The Pharma Data

JANUARY 11, 2021

Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. VIR-7832 is set to become the second monoclonal antibody from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment. SAN FRANCISCO and LONDON, Jan. George Scangos, Ph.D.,

Antibody 40

Antibody Clinical Trials Clinical Trials Trials 40

The Pharma Data

FEBRUARY 25, 2021

13 Therefore, it is able to induce neutralizing antibodies against the natural TBE virus, as the sequence and structure of the virus subtype match those found in nature. DISCLOSURE NOTICE: The information contained in this release is as of February 23, 2021. This release contains forward?looking Genome Announc.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 14, 2021

It is also approved in combination with bendamustine, followed by Gazyva/Gazyvaro maintenance for the treatment of FL patients who did not respond to a MabThera®/Rituxan® (rituximab)-containing regimen, or whose FL returned after such treatment and in combination with chemotherapy for previously untreated advanced FL. Source link: [link].

Medicine 52

Medicine In-Vitro Antibody Genome 52

The Pharma Data

SEPTEMBER 2, 2021

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs). Antibody drug conjugates. A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05). Antibody drug conjugates. Abstract #P47.11. 8 September 2021. Borghaei, H. Johnson, ML.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

JULY 6, 2021

Food and Drug Administration (FDA)-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy. 1)] as determined by a U.S. Head and Neck Squamous Cell Cancer.

FDA Approval 52

FDA Approval Containment Trials Genome 52

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. An RNA genome enables the genetic material to mutate more rapidly. While levels of neutralizing antibodies can be used to determine protection, it is not a defined universal criterion.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

The Pharma Data

MARCH 30, 2021

In Europe, KEYTRUDA is approved for the treatment of adult patients with advanced or metastatic urothelial carcinoma (bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a Combined Positive Score (CPS) ?10. About KEYTRUDA ® (pembrolizumab) Injection, 100 mg.

FDA Approval 52

FDA Approval Containment Trials Genome 52

Drug Discovery World

FEBRUARY 8, 2023

Partially-filled capsids may also be present, and contain packaged process-related impurities or truncated genetic material. Methods such as ELISA/qPCR offer well-established, sensitive, and specific analyses that can measure capsid titre versus genome titre, quantifying empty and full capsids 3.

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

The Pharma Data

MARCH 23, 2021

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy.

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

JULY 8, 2021

KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy.

FDA Approval 52

FDA Approval Containment Trials Genome 52

The Pharma Data

JANUARY 24, 2021

All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. VP-102 is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidim delivered by way of a single-use applicator. Non-COVID-19-Related. BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

AUGUST 6, 2020

FDA for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document.

Production 52

Production Branding Marketing Licensing 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1.

Immune Response 52

Immune Response Medicine Protein Gene 52

The Pharma Data

JULY 23, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Hormones 52

Hormones Trials Genome Genomics 52

Pharma Marketing Network

JANUARY 20, 2021

Perhaps this omission is because the systemically administered vaccines are unable to stimulate robust immune responses in the mucosae, despite generating systemic neutralizing antibody (and possibly T cell) responses.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

The Pharma Data

MARCH 11, 2021

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Trials 52

Trials Hormones Genome Genomics 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Embryo-Fetal Toxicity. It is not known whether OPDIVO or YERVOY is present in human milk.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Embryo-Fetal Toxicity. It is not known whether OPDIVO or YERVOY is present in human milk.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 The information contained in this release is as of November 3, 2022. COMIRNATY® (COVID-19 Vaccine, mRNA). INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

Drug Discovery World

SEPTEMBER 29, 2022

After the initial infection, CMV becomes latent, with the genome residing in cells but no virus particles generated to cause detectable damage or illness 7,8. Recombinant CMV vaccines used a modified version of a CMV protein and showed partial efficacy in preventing CMV infection but did not elicit the production of neutralising antibodies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

XTalks

MAY 31, 2021

The report contains new details that were not present in a State Department fact sheet about occurrences at the virology institute that was released earlier this year. He said researchers were tested and no evidence was found of COVID antibodies, and said the lab was “very well run,” suggesting a viral leak was unlikely.

Engineer 59

Engineer Scientist Genome Genomics 59